share_log

Could The Market Be Wrong About Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Its Attractive Financial Prospects?

Could The Market Be Wrong About Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Its Attractive Financial Prospects?

市場是否可能對和諧生物科學控股公司(納斯達克:HRMY)在財務前景吸引力方面存在誤判?
Simply Wall St ·  12/23 18:59

With its stock down 9.4% over the past three months, it is easy to disregard Harmony Biosciences Holdings (NASDAQ:HRMY). But if you pay close attention, you might gather that its strong financials could mean that the stock could potentially see an increase in value in the long-term, given how markets usually reward companies with good financial health. Particularly, we will be paying attention to Harmony Biosciences Holdings' ROE today.

在過去三個月中,其股價下跌了9.4%,很容易忽視和諧生物科學控股公司(納斯達克股票代碼:HRMY)。但是,如果你密切關注,你可能會發現,鑑於市場通常會獎勵財務狀況良好的公司,其強勁的財務狀況可能意味着該股的長期價值可能會增加。特別是,我們今天將關注和諧生物科學控股的投資回報率。

Return on Equity or ROE is a test of how effectively a company is growing its value and managing investors' money. In simpler terms, it measures the profitability of a company in relation to shareholder's equity.

股本回報率或投資回報率是對公司價值增長和管理投資者資金的有效性的考驗。簡而言之,它衡量公司相對於股東權益的盈利能力。

How To Calculate Return On Equity?

如何計算股本回報率?

ROE can be calculated by using the formula:

ROE 可以通過使用以下公式計算:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity

股本回報率 = 凈利潤(來自持續經營)÷ 股東權益

So, based on the above formula, the ROE for Harmony Biosciences Holdings is:

因此,根據上述公式,Harmony Biosciences Holdings的投資回報率爲:

21% = US$123m ÷ US$597m (Based on the trailing twelve months to September 2024).

21% = 1.23億美元 ÷ 5.97億美元(基於截至2024年9月的過去十二個月)。

The 'return' is the amount earned after tax over the last twelve months. So, this means that for every $1 of its shareholder's investments, the company generates a profit of $0.21.

「回報」 是過去十二個月的稅後收入。因此,這意味着公司每投資1美元,就會產生0.21美元的利潤。

What Has ROE Got To Do With Earnings Growth?

投資回報率與收益增長有什麼關係?

We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. Based on how much of its profits the company chooses to reinvest or "retain", we are then able to evaluate a company's future ability to generate profits. Generally speaking, other things being equal, firms with a high return on equity and profit retention, have a higher growth rate than firms that don't share these attributes.

我們已經確定,投資回報率是衡量公司未來收益的有效盈利指標。根據公司選擇再投資或 「保留」 的利潤金額,我們隨後能夠評估公司未來的盈利能力。一般而言,在其他條件相同的情況下,股本回報率和利潤保留率高的公司比不具備這些屬性的公司的增長率更高。

A Side By Side comparison of Harmony Biosciences Holdings' Earnings Growth And 21% ROE

Harmony Biosciences Holdings的收益增長和21%的投資回報率的並排比較

At first glance, Harmony Biosciences Holdings seems to have a decent ROE. And on comparing with the industry, we found that the the average industry ROE is similar at 21%. This certainly adds some context to Harmony Biosciences Holdings' exceptional 66% net income growth seen over the past five years. We reckon that there could also be other factors at play here. For instance, the company has a low payout ratio or is being managed efficiently.

乍一看,和諧生物科學控股公司的投資回報率似乎不錯。與行業相比,我們發現行業的平均投資回報率相似,爲21%。這無疑爲Harmony Biosciences Holdings在過去五年中實現的66%的驚人淨收入增長增添了一些背景信息。我們認爲,這裏可能還有其他因素在起作用。例如,該公司的派息率較低或管理效率很高。

Next, on comparing with the industry net income growth, we found that Harmony Biosciences Holdings' growth is quite high when compared to the industry average growth of 1.2% in the same period, which is great to see.

接下來,與行業淨收入增長相比,我們發現Harmony Biosciences Holdings的增長相當高,而同期的行業平均增長率爲1.2%,這真是太好了。

big
NasdaqGM:HRMY Past Earnings Growth December 23rd 2024
納斯達克通用汽車公司:HRMY 過去的收益增長 2024 年 12 月 23 日

Earnings growth is a huge factor in stock valuation. The investor should try to establish if the expected growth or decline in earnings, whichever the case may be, is priced in. This then helps them determine if the stock is placed for a bright or bleak future. Is Harmony Biosciences Holdings fairly valued compared to other companies? These 3 valuation measures might help you decide.

收益增長是股票估值的重要因素。無論如何,投資者應設法確定預期的收益增長或下降是否已計入其中。然後,這可以幫助他們確定股票是面向光明還是暗淡的未來。與其他公司相比,和諧生物科學控股的估值是否合理?這3種估值指標可能會幫助您做出決定。

Is Harmony Biosciences Holdings Efficiently Re-investing Its Profits?

和諧生物科學控股公司是否有效地將其利潤再投資?

Given that Harmony Biosciences Holdings doesn't pay any regular dividends to its shareholders, we infer that the company has been reinvesting all of its profits to grow its business.

鑑於Harmony Biosciences Holdings不向其股東支付任何定期股息,我們推斷該公司一直在將其所有利潤再投資以發展業務。

Conclusion

結論

Overall, we are quite pleased with Harmony Biosciences Holdings' performance. Specifically, we like that the company is reinvesting a huge chunk of its profits at a high rate of return. This of course has caused the company to see substantial growth in its earnings. With that said, the latest industry analyst forecasts reveal that the company's earnings growth is expected to slow down. To know more about the company's future earnings growth forecasts take a look at this free report on analyst forecasts for the company to find out more.

總體而言,我們對和諧生物科學控股的表現感到非常滿意。具體而言,我們喜歡該公司以高回報率再投資其利潤的很大一部分。當然,這導致該公司的收益大幅增長。話雖如此,最新的行業分析師預測顯示,該公司的收益增長預計將放緩。要了解有關公司未來收益增長預測的更多信息,請查看這份關於分析師預測的免費報告,以了解更多信息。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?擔心內容嗎?直接聯繫我們。或者,發送電子郵件給編輯組(網址爲)simplywallst.com。
Simply Wall ST 的這篇文章本質上是籠統的。我們僅使用公正的方法提供基於歷史數據和分析師預測的評論,我們的文章並非旨在提供財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不會考慮最新的價格敏感型公司公告或定性材料。華爾街只是沒有持有上述任何股票的頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論